IQ driving QI: The Asia pacific consortium on osteoporosis (APCO): An innovative and collaborative initiative to improve osteoporosis care in the Asia pacific

M Chandran, Singapore General Hospital, Singapore, Singapore
S K. Bhadada, Postgraduate Institute of Medical Education and Research (PGIMER), India
P R. Ebeling, Monash University, Melbourne, Australia
N L. Gilchris, Canterbury District Health Board, Christchurch, New Zealand
Aysha Habib Khan, Aga Khan University
P Halbout, International Osteoporosis Foundation, Nyon, Switzerland
S Lekamwasam, University of Ruhuna, Matara, Sri Lanka
G Lyubomirsk, Osteoporosis Australia, Sydney, Australia
P J. Mitchell, Synthesis Medical NZ Limited, Auckland, New Zealand
T V. Nguyen, The Garvan Institute of Medical Research, Sydney, Australia
K L. Tiu, Queen Elizabeth Hospital, Hong Kong, Hong Kong SAR.
Asia Pacific Consortium on Osteoporosis


Asia Pacific Consortium on Osteoporosis (APCO) comprises of clinical experts from across the Asia Pacific region, uniting to develop solutions to problems facing osteoporosis management and care. The vision of APCO is to reduce the burden of osteoporosis and fragility fractures in the Asia Pacific region.
Introduction: The Asia Pacific (AP) region comprises 71 countries with vastly different healthcare systems. It is predicted that by 2050, more than half the world's hip fractures will occur in this region. The Asia Pacific Consortium on Osteoporosis (APCO) was set up in May 2019 with the vision of reducing the burden of osteoporosis and fragility fractures in the AP region.
Methods: APCO has so far brought together 39 clinical experts from countries and regions across the AP to develop solutions to challenges facing osteoporosis management and fracture prevention in this highly populous region of the world. APCO aims to achieve its vision by engaging with relevant stakeholders including healthcare providers, policy makers and the public. The initial APCO project is to develop and implement a Framework of pan-AP minimum clinical standards for the screening, diagnosis and management of osteoporosis.
Results and conclusions: The Framework will serve as a platform upon which new national clinical guidelines can be developed or existing guidelines be revised, in a standardised fashion. The Framework will also facilitate benchmarking for provision of quality of care. It is hoped that the principles underlying the formation and functioning of APCO can be adopted by other regions and that every health care facility and progressively every country in the world can follow our aspirational path and progress towards best practice.